Forgue ST - Search Results

1

Tadalafil population pharmacokinetics in patients with erectile dysfunction.

Trocóniz IF, Tillmann C, Staab A, Rapado J, Forgue ST. Trocóniz IF, et al. Among authors: forgue st. Eur J Clin Pharmacol. 2007 Jun;63(6):583-90. doi: 10.1007/s00228-007-0297-1. Epub 2007 Apr 13. Eur J Clin Pharmacol. 2007. PMID: 17431603 Clinical Trial.

2

Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics.

Forgue ST, Phillips DL, Bedding AW, Payne CD, Jewell H, Patterson BE, Wrishko RE, Mitchell MI. Forgue ST, et al. Br J Clin Pharmacol. 2007 Jan;63(1):24-35. doi: 10.1111/j.1365-2125.2006.02726.x. Epub 2006 Jul 21. Br J Clin Pharmacol. 2007. PMID: 16869816 Free PMC article.

3

Model-based drug development: the road to quantitative pharmacology.

Zhang L, Sinha V, Forgue ST, Callies S, Ni L, Peck R, Allerheiligen SR. Zhang L, et al. Among authors: forgue st. J Pharmacokinet Pharmacodyn. 2006 Jun;33(3):369-93. doi: 10.1007/s10928-006-9010-8. Epub 2006 Jun 13. J Pharmacokinet Pharmacodyn. 2006. PMID: 16770528

4

Tadalafil pharmacokinetics in healthy subjects.

Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, Mitchell MI. Forgue ST, et al. Br J Clin Pharmacol. 2006 Mar;61(3):280-8. doi: 10.1111/j.1365-2125.2005.02553.x. Br J Clin Pharmacol. 2006. PMID: 16487221 Free PMC article.

5

Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo.

Ring BJ, Patterson BE, Mitchell MI, Vandenbranden M, Gillespie J, Bedding AW, Jewell H, Payne CD, Forgue ST, Eckstein J, Wrighton SA, Phillips DL. Ring BJ, et al. Among authors: forgue st. Clin Pharmacol Ther. 2005 Jan;77(1):63-75. doi: 10.1016/j.clpt.2004.09.006. Clin Pharmacol Ther. 2005. PMID: 15637532 Clinical Trial.

6

Population dose-response model for tadalafil in the treatment of male erectile dysfunction.

Staab A, Tillmann C, Forgue ST, Mackie A, Allerheiligen SR, Rapado J, Trocóniz IF. Staab A, et al. Among authors: forgue st. Pharm Res. 2004 Aug;21(8):1463-70. doi: 10.1023/b:pham.0000036922.03519.40. Pharm Res. 2004. PMID: 15359583 Clinical Trial.

7

Gemcitabine in patients with solid tumors and renal impairment: a pharmacokinetic phase I study.

Delaloge S, Llombart A, Di Palma M, Tourani JM, Turpin F, Ni L, Forgue ST, Le Chevalier T. Delaloge S, et al. Among authors: forgue st. Am J Clin Oncol. 2004 Jun;27(3):289-93. doi: 10.1097/01.coc.0000071382.14174.c5. Am J Clin Oncol. 2004. PMID: 15170150 Clinical Trial.

8

Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure.

Abraham E, Naum C, Bandi V, Gervich D, Lowry SF, Wunderink R, Schein RM, Macias W, Skerjanec S, Dmitrienko A, Farid N, Forgue ST, Jiang F. Abraham E, et al. Among authors: forgue st. Crit Care Med. 2003 Mar;31(3):718-28. doi: 10.1097/01.CCM.0000053648.42884.89. Crit Care Med. 2003. PMID: 12626975 Clinical Trial.

9

Confidence interval criteria for assessment of dose proportionality.

Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, Forgue ST. Smith BP, et al. Among authors: forgue st. Pharm Res. 2000 Oct;17(10):1278-83. doi: 10.1023/a:1026451721686. Pharm Res. 2000. PMID: 11145235

10

Pharmacokinetics of a 7-day 17 beta-estradiol transdermal delivery system: effect of application site and repeated applications on serum concentrations of estradiol and estrone.

Boyd RA, Yang BB, Abel RB, Eldon MA, Sedman AJ, Forgue ST. Boyd RA, et al. Among authors: forgue st. J Clin Pharmacol. 1996 Nov;36(11):998-1005. doi: 10.1177/009127009603601103. J Clin Pharmacol. 1996. PMID: 8973988 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

27 results

Search Page